All articles
Notable 2023 US Drug Approvals Ranked by Sales Estimates
Lilly leads with 4 entries. Notable diversification away from oncology into CNS, vaccines, and rare disease.
February 7, 2023
Download the Visual
Lilly leads the way with 4 entries, while Pfizer, AbbVie and GSK are also well represented.
In terms of therapeutic areas, we see a notable diversification away from oncology, with CNS (Alzheimer's, Parkinson's, MDD) and I&I (atopic dermatitis, ulcerative colitis, plaque psoriasis and alopecia) leading the way.
Most of these drugs have a wide band of sales estimates, so it's likely several will surprise in both directions.
Note: not exhaustive for all anticipated approvals
